An expanding role for cell biologists in drug discovery and pharmacology

The profound challenges facing clinicians, who must prescribe drugs in the face of dramatic variability in response, and the pharmaceutical industry, which must develop new drugs despite ever-rising costs, represent opportunities for cell biologists interested in rethinking the conceptual basis of pharmacology and drug discovery. Much better understanding is required of the quantitative behaviors of networks targeted by drugs in cells, tissues, and organisms. Cell biologists interested in these topics should learn more about the basic structure of drug development campaigns and hone their quantitative and programming skills. A world of conceptual challenges and engaging industry–academic collaborations awaits, all with the promise of delivering real benefit to patients and strained healthcare systems.

[1]  D. Gary Gilliland,et al.  Drug development and clinical trials—the path to an approved cancer drug , 2012, Nature Reviews Clinical Oncology.

[2]  Ravi Iyengar,et al.  Network analyses in systems pharmacology , 2009, Bioinform..

[3]  Timothy J. Mitchison,et al.  The proliferation rate paradox in antimitotic chemotherapy , 2012, Molecular biology of the cell.

[4]  Ralph Weissleder,et al.  Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics. , 2011, Cancer research.

[5]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[6]  A. Barabasi,et al.  Systems biology and the future of medicine , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.

[7]  I-Ming Wang,et al.  Systems biology approach for new target and biomarker identification. , 2013, Current topics in microbiology and immunology.

[8]  C. Sigman,et al.  Cancer biomarkers: selecting the right drug for the right patient , 2012, Nature Reviews Drug Discovery.

[9]  P. Chène Can biochemistry drive drug discovery beyond simple potency measurements? , 2012, Drug discovery today.

[10]  D. Huszar,et al.  Kinesin motor proteins as targets for cancer therapy , 2009, Cancer and Metastasis Reviews.

[11]  A. Letai,et al.  Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.

[12]  R. Lalonde,et al.  Introduction of Quantitative Methods in Pharmacology and Clinical Pharmacology: A Historical Overview , 2007, Clinical pharmacology and therapeutics.

[13]  Malorye Allison,et al.  NCATS launches drug repurposing program , 2012, Nature Biotechnology.